We are live on ! Find out more
VTGN icon

VistaGen Therapeutics
VTGN

101 hedge funds and large institutions have $387M invested in VistaGen Therapeutics in 2021 Q2 according to their latest regulatory filings, with 46 funds opening new positions, 23 increasing their positions, 22 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

142% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 19

71% more capital invested

Capital invested by funds: $227M → $387M (+$160M)

36% more funds holding

Funds holding: 74 → 101 (+27)

5% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 22

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.31% less ownership

Funds ownership: 2.46% → 2.15% (-0.31%)

Holders
101
Holders Change
+27
Holders Change %
+36.49%
% of All Funds
1.76%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
46
Increased
23
Reduced
22
Closed
19
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$22.2M
2
O
OrbiMed
New York
+$14.5M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$7.6M
4
State Street
State Street
Massachusetts
+$7.56M
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$4.88M

Top Sellers

Rank Fund Capital Flow
1
MWNA
Marshall Wace North America
New York
-$6.02M
2
GTC
Ghost Tree Capital
New York
-$5.29M
3
IC
Ikarian Capital
Texas
-$4.86M
4
Millennium Management
Millennium Management
New York
-$3.01M
5
SB
Samsara BioCapital
California
-$2.71M
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
51
ACT Capital Management
Pennsylvania
$315K +$247K +3,333 New
Invesco
52
Invesco
Georgia
$270K +$211K +2,852 New
MIM
53
MetLife Investment Management
New Jersey
$265K +$208K +2,803 New
VOYA Investment Management
54
VOYA Investment Management
Georgia
$240K +$188K +2,543 New
MHS
55
M Holdings Securities
Oregon
$205K +$2.52K +34 +2%
MLICM
56
Metropolitan Life Insurance Company (MetLife)
New York
$203K +$159K +2,146 New
T. Rowe Price Associates
57
T. Rowe Price Associates
Maryland
$179K +$42.6K +575 +44%
ProShare Advisors
58
ProShare Advisors
Maryland
$156K +$123K +1,654 New
Parallax Volatility Advisers
59
Parallax Volatility Advisers
California
$140K – – –
SO
60
STRS Ohio
Ohio
$139K +$109K +1,477 New
AllianceBernstein
61
AllianceBernstein
Tennessee
$125K +$97.8K +1,320 New
AB
62
Amalgamated Bank
New York
$109K +$85.5K +1,154 New
LPL Financial
63
LPL Financial
California
$95K -$24.7K -333 -25%
QSS
64
Quantitative Systematic Strategies
Florida
$92K -$252K -3,404 -78%
Principal Financial Group
65
Principal Financial Group
Iowa
$92K +$72.1K +973 New
Barclays
66
Barclays
United Kingdom
$76K +$10K +135 +20%
Commonwealth Equity Services
67
Commonwealth Equity Services
Massachusetts
$74K +$13.2K +178 +29%
IAN
68
Integrated Advisors Network
Texas
$69K – – –
CTA
69
Chesley Taft & Associates
Illinois
$63K – – –
GBA
70
Garrison Bradford & Associates
New York
$63K – – –
Legal & General Group
71
Legal & General Group
United Kingdom
$61K +$48K +648 New
BPA
72
Beacon Pointe Advisors
California
$60K +$47.1K +636 New
Susquehanna International Group
73
Susquehanna International Group
Pennsylvania
$59K -$578K -7,796 -93%
HFM
74
Hartford Financial Management
Connecticut
$50K – – –
AIP
75
Ameritas Investment Partners
Nebraska
$47K +$37K +500 New
1 2
3
4 5

VTGN Hedge Fund Activity: Q2 2021 in Review

101 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in VistaGen Therapeutics (VTGN) for Q2 2021, worth a combined $387M — up 71% from $227M a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new VTGN positions and 19 closed out — a net gain of 27 holders — while 23 added to existing stakes and 22 trimmed.

The largest buyer was BlackRock, adding an estimated $22.2M. The largest seller was Marshall Wace North America, exiting entirely with an estimated $6.02M sold.

  • 101 institutional investors held VistaGen Therapeutics (VTGN) as of Q2 2021, up from 74 in Q1 2021.
  • Funds reported $387M of VistaGen Therapeutics stock for Q2 2021, up 71% quarter-over-quarter.
  • 46 funds opened new VistaGen Therapeutics positions in Q2 2021 and 19 closed out, a net change of +27 holders.
  • The largest VistaGen Therapeutics buyer in Q2 2021 was BlackRock, an estimated $22.2M added.
  • The largest VistaGen Therapeutics seller in Q2 2021 was Marshall Wace North America, an estimated $6.02M sold.

Based on aggregated 13F filings for Q2 2021.